A source-led profile for the MedCore TB-500 10 mg research presentation, separating compound identity, FDA safety context and product-specific information.
TB-500 is listed by PubChem as a synthetic N-acetylated heptapeptide with the sequence LKKTETQ, PubChem CID 62707662, molecular formula C38H68N10O14 and molecular weight of about 889.0 g/mol.1
FDA materials describe TB-500 as a synthetic fragment corresponding to residues 17 through 23 of thymosin beta-4. This distinction matters because evidence relating to full-length thymosin beta-4 should not automatically be treated as evidence for the shorter TB-500 fragment.2
The strongest public sources establish the identity of the peptide and an important limitation: human exposure data for TB-500 drug products are not established in the FDA source set.
FDA states that compounded drugs containing the thymosin beta-4 fragment LKKTETQ, also known as TB-500, may pose immunogenicity risk related to aggregation and peptide impurities. FDA says it has not identified human exposure data for drug products containing this fragment.3
PubChem lists TB-500 as CID 62707662 and provides the sequence LKKTETQ, formula C38H68N10O14 and molecular weight 889.0 g/mol.1
FDA briefing material describes TB-500 as an N-acetylated seven-amino-acid fragment derived from thymosin beta-4 residues 17–23, helping distinguish it from full-length thymosin beta-4.2
This page does not transfer findings about full-length thymosin beta-4 to TB-500 and does not present TB-500 as an approved medicine or as having established human efficacy, dosing or safety.
The MedCore portfolio presents TB-500 as a clearly identified 10 mg research product. Scientific claims on this page refer to the compound or public source record, not to verified performance of the MedCore presentation itself.
Batch-specific analytical values, laboratory names, purity results, route or other specifications should be added only when supported by corresponding MedCore documentation.
Product identity and documentation remain separate from scientific literature so research claims are not converted into product claims.
Strength-specific documentation preview for the MedCore TB-500 research presentation.
These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.
Related compound pages strengthen topical connections while keeping each entity and its evidence distinct.
Concise answers built around source-supported identity, evidence limitations and MedCore product information.
Claims are limited to standardized identity and FDA source material rather than extrapolated therapeutic claims. Last reviewed 2 September 2026.
Standardized identity, sequence, molecular formula and molecular weight.
Open PubChem source ↗FDA characterization of TB-500 as a synthetic thymosin beta-4 fragment.
Open FDA briefing ↗FDA safety context and statement regarding lack of identified human exposure data for TB-500 drug products.
Open FDA source ↗Review the MedCore quality framework or contact the team for product-specific documentation.
